Rothschild Investment Corp IL increased its position in CVS Health Corp (NYSE:CVS) by 2.2% in the third quarter, Holdings Channel reports. The institutional investor owned 146,192 shares of the pharmacy operator’s stock after acquiring an additional 3,077 shares during the period. CVS Health comprises about 1.4% of Rothschild Investment Corp IL’s holdings, making the stock its 15th biggest position. Rothschild Investment Corp IL’s holdings in CVS Health were worth $11,508,000 as of its most recent SEC filing.
Several other large investors have also recently bought and sold shares of CVS. Adviser Investments LLC increased its position in CVS Health by 43.3% during the second quarter. Adviser Investments LLC now owns 2,993 shares of the pharmacy operator’s stock worth $193,000 after purchasing an additional 905 shares during the last quarter. Keystone Financial Planning Inc. increased its position in CVS Health by 44.5% during the second quarter. Keystone Financial Planning Inc. now owns 59,038 shares of the pharmacy operator’s stock worth $3,799,000 after purchasing an additional 18,176 shares during the last quarter. Schwab Charles Investment Management Inc. increased its position in CVS Health by 4.3% during the second quarter. Schwab Charles Investment Management Inc. now owns 7,332,665 shares of the pharmacy operator’s stock worth $471,857,000 after purchasing an additional 300,887 shares during the last quarter. Waddell & Reed Financial Inc. increased its position in CVS Health by 21.5% during the second quarter. Waddell & Reed Financial Inc. now owns 993,394 shares of the pharmacy operator’s stock worth $63,925,000 after purchasing an additional 175,725 shares during the last quarter. Finally, ICM Asset Management Inc. WA acquired a new position in CVS Health during the second quarter worth approximately $1,152,000. 82.88% of the stock is owned by institutional investors and hedge funds.
Several equities analysts recently commented on CVS shares. Royal Bank of Canada reaffirmed a “buy” rating and set a $90.00 price target on shares of CVS Health in a research report on Wednesday, August 8th. Citigroup reaffirmed a “buy” rating and set a $81.00 price target on shares of CVS Health in a research report on Monday, July 9th. Mizuho reaffirmed a “buy” rating on shares of CVS Health in a research report on Saturday, June 30th. Bank of America upped their price target on shares of CVS Health from $86.00 to $90.00 and gave the stock a “buy” rating in a research report on Monday, September 17th. Finally, ValuEngine raised shares of CVS Health from a “sell” rating to a “hold” rating in a research report on Thursday, October 11th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating, ten have assigned a buy rating and two have assigned a strong buy rating to the company. CVS Health currently has an average rating of “Buy” and an average target price of $86.31.
CVS Health (NYSE:CVS) last released its quarterly earnings data on Wednesday, August 8th. The pharmacy operator reported $1.69 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.61 by $0.08. CVS Health had a net margin of 1.61% and a return on equity of 18.25%. The company had revenue of $46.71 billion during the quarter, compared to analyst estimates of $46.34 billion. During the same quarter in the prior year, the business earned $1.33 earnings per share. The business’s quarterly revenue was up 2.2% compared to the same quarter last year. Research analysts anticipate that CVS Health Corp will post 7.05 EPS for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, November 1st. Stockholders of record on Wednesday, October 24th will be given a $0.50 dividend. This represents a $2.00 annualized dividend and a dividend yield of 2.70%. The ex-dividend date is Tuesday, October 23rd. CVS Health’s payout ratio is currently 33.90%.
In other news, EVP Eva C. Boratto sold 13,311 shares of the company’s stock in a transaction on Monday, September 17th. The shares were sold at an average price of $77.16, for a total value of $1,027,076.76. Following the completion of the transaction, the executive vice president now directly owns 55,162 shares in the company, valued at $4,256,299.92. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Lisa Bisaccia sold 21,534 shares of the company’s stock in a transaction on Monday, October 1st. The shares were sold at an average price of $80.00, for a total transaction of $1,722,720.00. The disclosure for this sale can be found here. Insiders sold 43,409 shares of company stock valued at $3,392,097 in the last three months. Company insiders own 0.53% of the company’s stock.
CVS Health Company Profile
CVS Health Corporation, together with its subsidiaries, provides integrated pharmacy health care services. It operates through Pharmacy Services and Retail/LTC segments. The Pharmacy Services segment offers pharmacy benefit management solutions, such as plan design and administration, formulary management, Medicare Part D services, mail order, specialty pharmacy and infusion services, retail pharmacy network management services, prescription management systems, clinical services, disease management programs, and medical pharmacy management services.
Featured Story: Return on Investment (ROI) Defined, Explained
Want to see what other hedge funds are holding CVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CVS Health Corp (NYSE:CVS).
Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.